Click Therapeutics

Click Therapeutics is redefining modern medicine by developing patient-centric digital treatments delivered via smartphone and prescribed by physicians. The company leverages a multimodal, platform-based approach that combines scientifically proven therapies with proprietary neuromodulatory mechanisms to drive clinically meaningful outcomes. With an FDA-cleared product for depression and multiple Phase 3 programs in neurology and psychiatry, Click is positioned at the forefront of the rapidly evolving digital therapeutics market. Their innovative Software-Enhanced Drugs™ platform represents a novel approach to enhancing traditional pharmacotherapy through digital interventions.

Multimodal platform combining scientifically proven therapies with proprietary neuromodulatory mechanisms to create Prescription Digital Therapeutics (PDTs) and Software-Enhanced Drugs™ that integrate software with pharmacotherapy for enhanced clinical outcomes.

Total raised: $104M

Competitors include Pear Therapeutics (bankrupt), Akili Interactive, Big Health, Woebot Health, Happify Health, and Kaia Health. Click differentiates through prescription-grade treatments with rigorous clinical validation, proprietary neuromodulatory mechanisms, and their innovative Software-Enhanced Drugs™ platform that integrates with traditional pharmacotherapy.